American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Baselga
    Baselga
  7. Berger
    Berger
  8. Norton
    Norton
  9. Reis-Filho
    Reis-Filho
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and tolerability of lete-cel in NSCLC—Reply
    Correspondence

    Altan, M.; Lopes, G.; Hiltermann, T. J. N.; Govindan, R.; Villaruz, L. C.; Calvo, E.; Edelman, M. J.; Furqan, M.; Neal, J.; Felip, E.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission
    Journal Article

    Kushner, B. H.; Modak, S.; Mauguen, A.; Basu, E. M.; Kramer, K.; Roberts, S. S.; Cheung, I. Y.; Cheung, N. K. V.
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma
    Journal Article

    Pal, S. K.; Bernard-Tessier, A.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; de Braud, F.; Takahashi, S.; Wong, A.; Suárez, C.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Phase I trial of selinexor in pediatric recurrent/refractory solid and CNS tumors (ADVL1414): A Children’s Oncology Group phase I consortium trial
    Journal Article

    Green, A. L.; Minard, C. G.; Liu, X.; Safgren, S. L.; Pinkney, K.; Harris, L.; Link, G.; DeSisto, J.; Voss, S.; Nelson, M. D.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • The lung cancer autochthonous model gene expression database enables cross-study comparisons of the transcriptomic landscapes across mouse models
    Journal Article

    Cai, L.; Wu, F.; Zhou, Q.; Gao, Y.; Yao, B.; DeBerardinis, R. J.; Acquaah-Mensah, G. K.; Aidinis, V.; Beane, J. E.; Biswal, S.; more...
    Cancer Research (2025)

    Fulltext@MSK | Save
  • Tumorigenesis driven by BRAF(V600E) requires secondary mutations that overcome its feedback inhibition of RAC1 and migration
    Journal Article

    Gadal, S.; Boyer, J. A.; Roy, S. F.; Outmezguine, N. A.; Sharma, M.; Li, H.; Fan, N.; Chan, E.; Romin, Y.; Barlas, A.; more...
    Cancer Research (2025)

    Fulltext@MSK | Save
  • Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer
    Journal Article

    Galsky, M. D.; Autio, K. A.; Cabanski, C. R.; Wentzel, K.; Graff, J. N.; Friedlander, T. W.; Howes, T. R.; Shotts, K. M.; Densmore, J.; Spasic, M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Can longitudinal biomarkers guide treatment decisions? Time will tell
    Editorial

    Jeng, M. Y.; Schoenfeld, A. J.
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Phase I study of adavosertib with radiotherapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma
    Journal Article

    Lee, E. Q.; Alexander, B. M.; Romo, C. G.; Supko, J. G.; Agar, N. Y. R.; Talebi, Z.; Ahluwalia, M. S.; Desai, A. S.; Dietrich, J.; Kaley, T. J.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Sacituzumab govitecan in patients with relapsed/refractory advanced head and neck squamous cell carcinoma: Results from the phase II TROPiCS-03 basket study
    Journal Article

    Michel, L.; Jimeno, A.; Sukari, A.; Beck, J. T.; Chiu, J.; Ahern, E.; Hilton, J.; Even, C.; Zanetta, S.; Mekan, S.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: